D-0896-2023 Class III Ongoing

Recalled by Vivus, Inc. — Campbell, CA

FDA drug recall D-0896-2023 was initiated by Vivus, Inc. on Jun 23, 2023 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is ongoing. Affected quantity: 4240 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 19, 2023
Initiation Date
Jun 23, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4240 bottles

Product description

PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10,

Reason for recall

Failed Stability Specifications

Distribution pattern

Nationwide within the United States

Code information

Lot #: 102101, Exp: 31 July 2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0896-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0896-2023. Report a data issue: hello@regdatalab.com.